Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Makaleler > Tam Makale · 2016
Yazarlar: A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, T Silovski, Erhan GÖKMEN, Minckwitz von, B Ejlertsen, SK Chia, J Mansi, CH Barrios, M Gnant, M Buyse, I Gore, J Smith, G Harker, N Masuda, K Petrakova, AG Zotano, N Iannotti, G Rodriguez, P Tassone, A Wong, R Bryce, Y Ye, B Yao, M Martin, Study ExteNET
The Lancet Oncology, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2016, cilt 17, ss 367-377